Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Directors Roster: a quarterly record of new director appointments
- THE DIRECTORS & BOARDS Directors Roster--a quarterly record of new director appointments--is compiled from public and private sources by the editorial staff of DIRECTORS & BOARDS and is sponsored by Heidrick & Struggles. Please forward your directors' appointments to kmccarthy@directorsandboards.com. Submissions of new directors and appointments are welcome from...
- Research articles 2007-03-22
- Amylin's Eastham Says Eastbourne's Behrens Is Not Telling the Truth About $20 Share Bid
- Amylin director Karin Eastham has, in essence, called Eastbourne Capital board candidate M. Kathleen Behrens a liar or at least an amnesiac. by Jim Edwards
- Blog posts 2009-05-14
- Amylin v. Eastbourne Slideshow Battle; It's All About the Stock Price
- Amylin and Eastbourne Capital, locked in a fight for control of Amylin's board of directors, have escalated their war in the only way that beancounters know how: duelling presentations. You can see Amylin's here and a summary of Eastbourne's here. Eastbourne has kept it...
- Blog posts 2009-05-06
- In U-Turn, Amylin Lays Off 200; Move Validates Icahn's Arguments
- Amylin says it will lay off 200 drug sales reps, or 35 percent of its force, in order to save $45 billion in costs. The move is an embarrassing U-turn for Amylin, which only days ago was arguing fiercely that after laying off 340 people last November it had cut...
- Blog posts 2009-05-05
- Amylin Trial Testimony: Debt Not Structured With Interest or Principal Payments in Mind
- Amylin's "poison put" debt deals were not structured primarily to protect interest and principal payments but to trigger a sudden bulk repayment, according to Professor Michael Roberts of Harvard Business School. by Jim Edwards
- Blog posts 2009-05-05
- The War for Amylin: Lilly Not Interested; Icahn Calls the Company a "Dictatorship"
- Eli Lilly CEO John Lechleiter complicated the battle for Amylin today by telling Reuters he was not interested in buying the company. It was widely suspected that investor Carl Icahn, who is in a three-way war for control of Amylin's board of directors, wants to dress up...
- Blog posts 2009-04-28
- Arena Lays Off 31% of Its Staff Following Obesity Trial Failure
- Arena Pharmaceuticals is to lay off 31 percent, or 130 employees, before June 22, the company told the SEC. Arena staffers -- whose future is dependent on an anti-obesity drug, lorcaserin -- may be forgiven for wondering how it has all gone wrong so quickly. In February, Arena CEO...
- Blog posts 2009-04-27
- Amylin CEO Got 11% Pay Rise Despite Losses; Company Paid $355K for Lawyer to Move House
- Combined executive pay at Amylin rose 10.2 percent last year even though the company lost 50 percent more money than it did the year before, according to a filing with the SEC. Amylin has not made a profit in the last five years, despite its revenues going from zero to...
- Blog posts 2009-04-22
- Amylin Insists Byetta Doesn't Cause Cancer; Wall Street Doesn't Seem So Sure
- Amylin CEO Daniel Bradbury may be wishing that Novo Nordisk's failed competitor to its diabetes drug Byetta had actually been approved by the FDA. Had Novo's liraglutide passed muster, no one would have gotten the jitters over whether Byetta gives you cancer or not. At Amylin's conference...
- Blog posts 2009-04-21
- Inside Amylin's Anti-Icahn Suicide Pact
- Amylin has adopted a financial suicide pact which, in the company's own words, may bankrupt the company if dissident investors Carl Icahn and Eastbourne Capital get a majority of directors elected at the May 27 shareholder meeting. The pact is described in a lawsuit brought by a...
- Blog posts 2009-04-01
- Amylin Battle Heats Up as Eastbourne Capital Touts Rival Directors' Slate to Icahn's
- Eastbourne Capital has proposed a five-member team of its own for Amylin's board. Carl Icahn proposed his own slate last week. Both sets of investors are unhappy with the company that has a joint venture with Eli Lilly on diabetes drug Byetta. Eastbourne said of its move:...
- Blog posts 2009-02-02
Additional Resources
- Amylin Q1: "Icahn Doesn't Know Who Our CEO Is"
- Amylin filed a sarcastic letter describing phone conversations it had with angry investor Carl Ichan over the past few days. "Sarcastic," because the final point in the letter which you can read here is this: Finally, on our call you asked, "Who is Dan Bradbury?" Dan Bradbury is Amylin’s...
- Blog posts 2009-04-20
- Amylin Founder Resigns, Suggests Chairman Follow; Icahn and Eastbourne Likely Delighted
- The Amylin board of directors is crumbling in its resistance to insurgent investors Carl Icahn and Eastbourne Capital. Amylin founder Howard Greene resigned as director and wrote a letter suggesting that chairman Joseph Cook should also step down. Greene said he won’t vote for Cook because: A majority of...
- Blog posts 2009-04-10
- Icahn Moves on Amylin; Will Lilly Step Up?
- BNET's 10-Q Detective, David Phillips, reports that Carl Icahn has filed papers to nominate a slate of directors for the board of Amylin, maker of diabetes drug Byetta. The last time Icahn interfered with a smaller company, ImClone, it ended up being bought by Eli Lilly. Here's...
- Blog posts 2009-01-30
- What Amylin's Established Drugs Are Worth Alone
- Vincent Fernando submits: Admittedly, my blog has become a bit of a war room in regard to the special situation surrounding Amylin AMLN shares these days. I personally find it to be an extremely interesting special situation and now have exposure to the shares. A lot of analysis...
- External links 2009-05-13
- Key Amylin Catalyst Expected Wednesday
- Vincent Fernando submits: A major battle for change at Amylin Pharmaceuticals AMLN could be decided this Wednesday when the company has its annual shareholder meeting and shareholders vote for a potentially new slate of board members put forward by activist shareholders Carl Icahn and Eastbourne Capital. Nevertheless, despite heated...
- External links 2009-05-24
- Elusive amylin: a perplexing protein may muddle insulin's message - Type II diabetes
- Elusive Amylin Biochemist Garth J.S. Cooper believes a protein called amylin underlies Type II diabetes. If he's right, drugs that block amylin might someday offer a new treatment for millions of people with the disease. If he's wrong, his theory will at least have sparked some illuminating...
- Research articles 1990-10-20
- Icahn Bruising For Proxy Battle With Amylin Management
- [caption id="attachment_248" align="alignleft" width="200" caption="Byetta"][/caption] Activist investor Carl Icahn announced in a regulatory filing with the Securities and Exchange Commission his intention to nominate a slate of five directors to the board of Amylin Pharmaceuticals at the drugmaker’s May 2009 annual...
- Blog posts 2009-01-29
- Ginger L. Graham. (Jobs and People).(is becoming president and CEO of Amylin Pharmaceuticals Inc.)(Brief Article)
- Ginger L. Graham has been named president and CEO of Amylin Pharmaceuticals Inc. effective September 1. Recently, Ms. Graham worked with Guidant Corp., where she was group chairman, office of ... Ginger L. Graham has been named president and CEO of Amylin Pharmaceuticals Inc....
- Research articles 2003-06-16
- Why I'm Buying Amylin Now
- Trader Mark submits: I'm following the "buy the busted stocks" instead of breakouts methodology, but breaking a rule on buying individual biotech stocks with today's purchase of Amylin Pharmaceuticals AMLN. This is one of the few biotechs I know pretty well, and have followed for quite a while - mostly...
- External links 2008-08-20
- << Previous
- page 1 of 1
- Next >>
